Global Leading Market Research Publisher QYResearch announces the release of its latest report “Oncology Precision Medicine – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032” . Leveraging over 19 years of industry expertise and a database exceeding 100,000 reports, QYResearch provides authoritative analysis trusted by more than 60,000 clients worldwide across critical sectors including Pharmaceuticals, Medical Care, Biotechnology, and Diagnostics. This report delivers a crucial roadmap for pharmaceutical executives, biotechnology innovators, diagnostic company leaders, and healthcare investors navigating the most transformative shift in cancer care since the advent of chemotherapy.
The global market for Oncology Precision Medicine was estimated to be worth US$ 38,530 million in 2024 and is forecast to reach a readjusted size of US$ 51,520 million by 2031, growing at a compound annual growth rate (CAGR) of 4.3% during the forecast period 2025-2031. This substantial and sustained growth occurs against a backdrop of a global medical devices market estimated at US$ 603 billion in 2023 (growing at a CAGR of 5%), and healthcare spending that now represents approximately 10% of global GDP. For oncologists, patients, and healthcare systems, the core challenge has always been the heterogeneity of cancer—a single diagnosis like “breast cancer” or “lung cancer” encompasses a multitude of distinct genetic and molecular subtypes, each responding differently to treatment. The “one-size-fits-all” approach leads to variable outcomes, unnecessary toxicity, and significant waste of healthcare resources. Oncology precision medicine offers a paradigm-shifting solution: the tailoring of prevention, diagnosis, and treatment to the individual characteristics of each patient’s cancer. By leveraging a deep understanding of the tumor’s genomic drivers, this approach integrates precision diagnostics to identify specific molecular targets and precision therapeutics to attack those targets with greater efficacy and less harm. This convergence of advanced technologies—from next-generation sequencing to targeted therapies and immunotherapies—is fundamentally reshaping the landscape of cancer care, offering new hope for patients with even the most challenging malignancies, from breast cancer and lung cancer to colorectal cancer, prostate cancer, and cervical cancer.
Defining the Ecosystem: The Four Pillars of Precision Oncology
Oncology precision medicine is not a single product but an integrated ecosystem of technologies and approaches. As detailed in the QYResearch report, it is segmented into four key areas that work together to deliver personalized cancer care:
- Applied Sciences: This foundational segment encompasses the basic research and discovery tools that fuel precision medicine. It includes genomics, proteomics, and other “omics” technologies used to identify new cancer drivers, understand resistance mechanisms, and develop novel therapeutic targets.
- Precision Diagnostics: This is the critical “identification” layer of precision medicine. It includes a range of in vitro diagnostic tests, such as next-generation sequencing (NGS) panels, polymerase chain reaction (PCR) assays, and immunohistochemistry (IHC), used to profile a patient’s tumor. These tests identify specific genetic mutations, protein expression levels, and other biomarkers that determine which targeted therapies are most likely to be effective. Companies like Illumina, Qiagen, Myriad Genetics, and Foundation Medicine (part of Roche) are leaders in this space.
- Digital Health and Information Technology: This rapidly growing segment provides the infrastructure to manage, analyze, and interpret the vast amounts of data generated by precision diagnostics. It includes bioinformatics platforms, clinical decision support tools, and electronic health records integrated with genomic data. These tools are essential for translating complex molecular data into actionable insights for clinicians.
- Precision Therapeutics: This is the “action” layer—the drugs and biologics designed to target the specific molecular drivers identified by diagnostics. It includes a wide range of therapies, from small molecule inhibitors (like Gleevec, Tagrisso) and monoclonal antibodies (like Herceptin) to advanced immunotherapies (like checkpoint inhibitors) and cell therapies (like CAR-T). Pharmaceutical giants like Roche, Novartis, Bristol Myers Squibb, Gilead Sciences, and Abbott Laboratories are at the forefront of developing and commercializing these targeted agents.
These tools are applied across the spectrum of cancer types, with major focus areas including breast cancer (e.g., HER2 testing and therapies), lung cancer (e.g., EGFR, ALK, and PD-L1 testing), colorectal cancer (e.g., RAS testing), prostate cancer (e.g., PARP inhibitors for BRCA-mutated tumors), cervical cancer (e.g., HPV testing), and numerous other solid tumors and hematologic malignancies.
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
(https://www.qyresearch.com/reports/4033897/oncology-precision-medicine)
Key Industry Trends Reshaping the Market
Based on analysis of recent regulatory approvals, clinical trial data, and market dynamics, four pivotal trends are defining the Oncology Precision Medicine market through 2031.
1. The Expansion of Biomarker-Driven Therapies and Companion Diagnostics
The number of cancer therapies approved with a required or recommended companion diagnostic is growing rapidly. Regulatory agencies like the FDA and EMA increasingly require evidence of a therapy’s efficacy in a biomarker-selected population. This trend cements the link between precision diagnostics and precision therapeutics, creating a powerful, symbiotic commercial model. For example, a new drug for a specific lung cancer mutation is developed and approved alongside a diagnostic test to identify patients with that mutation. This ensures the right patients receive the right drug, improving outcomes and cost-effectiveness. This model is expanding beyond classic oncogenes to include biomarkers like tumor mutational burden (TMB), microsatellite instability (MSI), and homologous recombination deficiency (HRD), which are agnostic to tumor type. Companies like Agilent Technologies, Bio-Rad Laboratories, and BioMérieux are key players in developing these companion diagnostics.
2. The Rise of Liquid Biopsy and Minimal Residual Disease (MRD) Monitoring
Tissue biopsies remain the gold standard for initial diagnosis, but they are invasive, can be difficult to obtain, and only provide a snapshot of the tumor at one point in time. Liquid biopsy, which analyzes circulating tumor DNA (ctDNA) from a simple blood draw, is transforming cancer management. It enables non-invasive tumor profiling at diagnosis, real-time monitoring of treatment response, and early detection of resistance mutations. Furthermore, the use of liquid biopsy for detecting minimal residual disease (MRD) after surgery or therapy is emerging as a powerful tool to identify patients at high risk of relapse months before clinical imaging can detect a recurrence. This is a game-changer for post-treatment surveillance. Companies like ANGLE plc, Guardant Health, and Natera (not listed but a key player) are driving this revolution, with BGI Group and Pacific Biosciences providing enabling sequencing technologies.
3. The Integration of Multi-Omics and Data Science
The complexity of cancer biology means that no single biomarker can fully capture a tumor’s behavior. The future of precision oncology lies in integrating data from multiple “omics” layers—genomics, transcriptomics, proteomics, and metabolomics—along with clinical and imaging data. This requires sophisticated bioinformatics and AI-powered analytics to identify complex signatures that predict response or resistance. Digital health and information technology is therefore becoming an increasingly critical component of the precision medicine ecosystem. Companies that can provide platforms to integrate, analyze, and interpret this multi-dimensional data will be essential partners for both diagnostic labs and clinicians.
4. The Globalization of Precision Medicine and the Role of Emerging Markets
While the initial adoption of precision oncology was concentrated in North America and Europe, its use is expanding rapidly in emerging markets, particularly in Asia. This is driven by several factors: the rising incidence of cancer in these regions, growing healthcare expenditure, improving infrastructure, and the decreasing cost of sequencing technologies. However, significant challenges remain, including variability in regulatory pathways, reimbursement models, and the availability of trained personnel. The expansion of emerging markets, which is a key driver of overall healthcare spending growth, presents a significant long-term opportunity for companies like Konica Minolta (with its healthcare IT focus), LabCorp, Quest Diagnostics, MDxHealth, and OPKO Health, who can offer scalable and cost-effective precision medicine solutions.
Market Segmentation and Strategic Outlook
The market is strategically segmented by technology pillar and by cancer type:
- By Type (Applied Sciences, Precision Diagnostics, Digital Health, Precision Therapeutics): Precision Therapeutics represents the largest share of market value, reflecting the high cost of targeted cancer drugs. Precision Diagnostics is the essential enabling segment, growing rapidly with the expansion of biomarker testing. Digital Health is the smallest but fastest-growing segment, critical for data management and interpretation.
- By Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Other Cancer): Lung cancer and breast cancer are the largest segments, due to their high prevalence and the availability of numerous targeted therapies. Colorectal, prostate, and other cancers are also significant and growing markets.
Exclusive Insight: The next major strategic frontier is the convergence of precision oncology with immuno-oncology and the development of personalized cancer vaccines. As we learn more about the interaction between a tumor’s genetics and the immune system, we are seeing the development of therapies that combine targeted agents with immunotherapies. Furthermore, the ability to sequence a patient’s tumor and identify unique neoantigens is paving the way for truly personalized cancer vaccines, designed to stimulate the patient’s own immune system to attack their specific cancer. This represents the ultimate realization of the precision medicine promise—a therapy engineered for one individual’s unique cancer. This frontier requires unprecedented levels of collaboration between diagnostic companies, bioinformatics firms, and therapeutic developers, involving players like Asuragen, Almac, and others in the ecosystem. It also demands new regulatory and reimbursement frameworks that can accommodate these highly individualized treatments.
For pharmaceutical executives, diagnostic company leaders, and healthcare investors, the strategic implication is clear. Oncology precision medicine is no longer a niche concept but the central organizing principle of modern cancer care. Success in this market requires a deep integration of diagnostics and therapeutics, mastery of complex data, and a focus on delivering tangible value to patients and healthcare systems. Companies featured in the QYResearch report—from diagnostics pioneers to pharmaceutical giants—are at the forefront of this transformation, working to make personalized cancer care a reality for patients around the world.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
